RLAY

Relay Therapeutics (RLAY) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov^[4], including 1 Phase 3^[1], 1 Phase 2^[2], 1 Phase 1^[3].

Trial NCT06982521^[5] evaluates RLY-2608 in PIK3CA Mutation with a target enrollment of 540 participants.

RLAY has 1 Form 4 insider filing recorded at the SEC in the past 30 days^[6].